Medidata Joins American Telemedicine Association Decentralized Clinical Trials (DCT) Special Interest Group

Medidata, a Dassault Systèmes company, has joined the American Telemedicine Association (ATA) to jointly drive the adoption and use of decentralized health technologies in clinical trials. As a member, Medidata reinforces its leadership in the development of best practices for decentralized clinical trials and standards surrounding patient engagement and the use of sensor and medical device data.

“Medidata is excited to be working with the ATA and its Decentralized Clinical Trials (DCT) Special Interest Group (SIG),” said Anthony Costello, President, Patient Cloud at Medidata. “We’re looking forward to collaborating and sharing insights with our digital health colleagues to create and advocate for increasingly patient-centric approaches to clinical research.”

The impacts of the COVID-19 pandemic have accelerated the adoption of decentralized clinical trial strategies. A decentralized approach can make it easier for patients to participate in clinical research by reaching a more diverse patient population and eliminating a handful of existing barriers to participation in studies, including COVID-related limitations. The goals of the DCT SIG include:

  • Pursuing policy/advocacy to remove barriers to interstate work
  • Creating practice guidelines to leverage existing telehealth and remote patient monitoring solutions
  • Addressing issues of data flow, a subset of the group’s work on telehealth interoperability

“We’re delighted to welcome Medidata’s participation in the Special Interest Group to advance policy and best practice guidelines for decentralized clinical trials,” said James Mault, MD, CEO of BioIntelliSense, and chair of the ATA’s Decentralized Clinical Trials SIG. “There are tremendous cost efficiencies and connected experiences that can be gained by bringing clinical trials to the patient and capturing medical-grade data from the home.”

Medidata brings unparalleled insight to the DCT SIG, as the leader in offering the most comprehensive set of unified technologies that enable full decentralization across the clinical trial continuum. Remote trials may have seemed unusual before, but COVID-19 is transforming how drug and vaccine developers (sponsors) and contract research organizations (CROs) are conducting clinical trials. These changes are also enhancing the patient experience by increasing engagement and participation.

For more information, contact Paul Oestreicher, external communications director at

View this post on